| Delineating the role of various factors in renal disposition of digoxin through application of physiologically based kidney model to renal impairment populations D Scotcher, CR Jones, A Galetin, A Rostami-Hodjegan Journal of Pharmacology and Experimental Therapeutics 360 (3), 484-495, 2017 | 58 | 2017 |
| Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance D Scotcher, C Jones, A Rostami-Hodjegan, A Galetin European Journal of Pharmaceutical Sciences 94, 59-71, 2016 | 48 | 2016 |
| Key to Opening Kidney for In Vitro–In Vivo Extrapolation Entrance in Health and Disease: Part I: In Vitro Systems and Physiological Data D Scotcher, C Jones, M Posada, A Rostami-Hodjegan, A Galetin The AAPS journal 18, 1067-1081, 2016 | 43 | 2016 |
| Microsomal and cytosolic scaling factors in dog and human kidney cortex and application for in vitro-in vivo extrapolation of renal metabolic clearance D Scotcher, S Billington, J Brown, CR Jones, CDA Brown, ... Drug Metabolism and Disposition 45 (5), 556-568, 2017 | 37 | 2017 |
| Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part II: Mechanistic Models and In Vitro-In Vivo Extrapolation D Scotcher, C Jones, M Posada, A Galetin, A Rostami-Hodjegan The AAPS journal 18, 1082-1094, 2016 | 37 | 2016 |
| Quantitative Translation of Microfluidic Transporter in Vitro Data to in Vivo Reveals Impaired Albumin-Facilitated Indoxyl Sulfate Secretion in Chronic Kidney Disease TK Van Der Made, M Fedecostante, D Scotcher, A Rostami-Hodjegan, ... Molecular pharmaceutics 16 (11), 4551-4562, 2019 | 36 | 2019 |
| Mass spectrometry‐based abundance atlas of ABC transporters in human liver, gut, kidney, brain and skin ZM Al‐Majdoub, B Achour, N Couto, M Howard, Y Elmorsi, D Scotcher, ... FEBS letters 594 (23), 4134-4150, 2020 | 25 | 2020 |
| Towards further verification of physiologically-based kidney models: predictability of the effects of urine-flow and urine-pH on renal clearance T Matsuzaki, D Scotcher, AS Darwich, A Galetin, A Rostami-Hodjegan Journal of Pharmacology and Experimental Therapeutics 368 (2), 157-168, 2019 | 23 | 2019 |
| Mechanistic models as framework for understanding biomarker disposition: prediction of creatinine‐drug interactions D Scotcher, V Arya, X Yang, P Zhao, L Zhang, SM Huang, ... CPT: Pharmacometrics & Systems Pharmacology 9 (5), 282-293, 2020 | 21 | 2020 |
| Physiologically‐based pharmacokinetic modelling of creatinine‐drug interactions in the chronic kidney disease population H Takita, D Scotcher, R Chinnadurai, PA Kalra, A Galetin CPT: Pharmacometrics & Systems Pharmacology 9 (12), 695-706, 2020 | 20 | 2020 |
| Clinical investigation on endogenous biomarkers to predict strong OAT-mediated drug–drug interactions ME Willemin, TK Van Der Made, I Pijpers, L Dillen, A Kunze, S Jonkers, ... Clinical Pharmacokinetics 60, 1187-1199, 2021 | 19 | 2021 |
| A novel physiologically based model of creatinine renal disposition to integrate current knowledge of systems parameters and clinical observations D Scotcher, V Arya, X Yang, P Zhao, L Zhang, SM Huang, ... CPT: Pharmacometrics & Systems Pharmacology 9 (6), 310-321, 2020 | 18 | 2020 |
| Scaling factors for clearance in adult liver cirrhosis E El-Khateeb, B Achour, D Scotcher, ZM Al-Majdoub, V Athwal, J Barber, ... Drug Metabolism and Disposition 48 (12), 1271-1282, 2020 | 17 | 2020 |
| Quantitative proteomic map of enzymes and transporters in the human kidney: stepping closer to mechanistic kidney models to define local kinetics ZM Al‐Majdoub, D Scotcher, B Achour, J Barber, A Galetin, ... Clinical Pharmacology & Therapeutics 110 (5), 1389-1400, 2021 | 16 | 2021 |
| Effect of chronic kidney disease on the renal secretion via organic anion transporters 1/3: implications for physiologically‐based pharmacokinetic modeling and dose adjustment SPF Tan, D Scotcher, A Rostami‐Hodjegan, A Galetin Clinical Pharmacology & Therapeutics 112 (3), 643-652, 2022 | 12 | 2022 |
| Coproporphyrin I as an endogenous biomarker to detect reduced OATP1B activity and shift in elimination route in chronic kidney disease H Takita, D Scotcher, X Chu, KL Yee, K Ogungbenro, A Galetin Clinical Pharmacology & Therapeutics 112 (3), 615-626, 2022 | 11 | 2022 |
| Physiologically based pharmacokinetic modeling of transporter-mediated hepatic disposition of imaging biomarker Gadoxetate in rats D Scotcher, N Melillo, S Tadimalla, AS Darwich, S Ziemian, ... Molecular Pharmaceutics 18 (8), 2997-3009, 2021 | 11 | 2021 |
| Hepatic scaling factors for in vitro–in vivo extrapolation of metabolic drug clearance in patients with colorectal cancer with liver metastasis AM Vasilogianni, B Achour, D Scotcher, SA Peters, ZM Al-Majdoub, ... Drug Metabolism and Disposition 49 (7), 563-571, 2021 | 10 | 2021 |
| Noninvasive preclinical and clinical imaging of liver transporter function relevant to drug-induced liver injury JG Kenna, JC Waterton, A Baudy, A Galetin, CDG Hines, P Hockings, ... Drug-Induced Liver Toxicity, 627-651, 2018 | 8 | 2018 |
| PBPK simulation-based evaluation of ganciclovir crystalluria risk factors: effect of renal impairment, old age, and low fluid intake D Scotcher, A Galetin The AAPS Journal 24, 1-17, 2022 | 7 | 2022 |
